> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Holds 4.4% Of Replimune Common Stock In Passive Position
- URL: https://www.bullished.co/state-street-holds-4-4-of-replimune-common-stock-in-passive-position-5c584f43/
- Published: 2026-11-10T15:17:45.000Z
- Updated: 2026-11-10T15:17:45.000Z
- Description: The September 30 holding comprised 4,174,260 shares, with State Street certifying it was not held to influence control.
- Author: Matteo Parrino
- Tags: SEC Filings, REPL, Industry: Healthcare

State Street reported a [4.4% stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000716/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Replimune](https://www.bullished.co/tag/repl/), which develops experimental cancer immunotherapies, in a passive ownership disclosure filed with the SEC Tuesday. The 4,174,260-share position reflects holdings as of September 30, rather than a purchase on the filing date.

## A Passive Holding, With Shared Votes

State Street certified that the securities were bought and held as part of its ordinary business, without a purpose or effect of changing or influencing Replimune's control.

The position carried [shared voting power](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000716/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) over 4,080,714 shares and shared authority to dispose of 4,174,260 shares. State Street reported zero sole voting power.

The disclosure also named SSGA Funds Management, State Street Global Advisors Europe and State Street Global Advisors Trust Company.

## Cancer Treatments Still In Development

Replimune has no products approved for sale. Its treatments use an engineered herpes simplex virus to destroy tumors and enlist the immune system against cancer, according to its annual report for the fiscal year ended March 31, 2026.

Its lead candidate, RP1, is being tested chiefly in advanced melanoma and other skin cancers. RP2 is being studied in liver cancers and metastatic uveal melanoma, an eye cancer that has spread. Both candidates are injected into tumors.

Replimune's trial partners include Bristol Myers Squibb and Roche. The company also operates a manufacturing facility of approximately 63,000 square feet in Framingham, Massachusetts.

Replimune's market capitalization was $2.1 billion in Tuesday trading as of 10:02 a.m. ET.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: REPLIMUNE GROUP INC (REPL)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000716/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR

### More on Replimune Group

- [Replimune Stock Jumps 9.73% After First Quarter Selling Its Melanoma Drug Tudriqev](https://www.bullished.co/replimune-stock-jumps-9-73-after-first-quarter-selling-its-melanoma-drug-tudriqev-f2c33eff/)
- [Replimune Says Tudrakev Accounts Could Double By Year-End, With Some Hospitals Skipping Formulary Review](https://www.bullished.co/replimune-says-tudrakev-accounts-could-double-by-year-end-with-some-hospitals-skipping-140014e6/)
- [Replimune Counts Accounts, Not Patients, For Its Tudrakev Launch — And Offers No Revenue Guidance](https://www.bullished.co/replimune-counts-accounts-not-patients-for-its-tudrakev-launch-and-offers-no-revenue-e51a69d3/)

[All Replimune Group (REPL) coverage →](https://www.bullished.co/tag/repl/)